These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32169475)

  • 1. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
    Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
    J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KLK5 Inactivation Reverses Cutaneous Hallmarks of Netherton Syndrome.
    Furio L; Pampalakis G; Michael IP; Nagy A; Sotiropoulou G; Hovnanian A
    PLoS Genet; 2015 Sep; 11(9):e1005389. PubMed ID: 26390218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
    Kishibe M
    J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A proinflammatory role of KLK6 protease in Netherton syndrome.
    Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
    J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome.
    Furio L; de Veer S; Jaillet M; Briot A; Robin A; Deraison C; Hovnanian A
    J Exp Med; 2014 Mar; 211(3):499-513. PubMed ID: 24534191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
    Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
    Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
    Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
    Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
    Hovnanian A
    Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
    Zingkou E; Pampalakis G; Sotiropoulou G
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LEKTI domains D6, D7 and D8+9 serve as substrates for transglutaminase 1: implications for targeted therapy of Netherton syndrome.
    Wiegmann H; Valentin F; Tarinski T; Liebau E; Loser K; Traupe H; Oji V
    Br J Dermatol; 2019 Nov; 181(5):999-1008. PubMed ID: 30801672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Netherton Syndrome: Insights into Pathogenesis and Clinical Implications.
    Chiticariu E; Hohl D
    J Invest Dermatol; 2020 Jun; 140(6):1129-1130. PubMed ID: 32446331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KLK5 and KLK7 Ablation Fully Rescues Lethality of Netherton Syndrome-Like Phenotype.
    Kasparek P; Ileninova Z; Zbodakova O; Kanchev I; Benada O; Chalupsky K; Brattsand M; Beck IM; Sedlacek R
    PLoS Genet; 2017 Jan; 13(1):e1006566. PubMed ID: 28095415
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Potent and Selective Kallikrein-5 Inhibitor Delivers High Pharmacological Activity in Skin from Patients with Netherton Syndrome.
    Liddle J; Beneton V; Benson M; Bingham R; Bouillot A; Boullay AB; Brook E; Cryan J; Denis A; Edgar E; Ferrie A; Fouchet MH; Grillot D; Holmes DS; Howes A; Krysa G; Laroze A; Lennon M; McClure F; Moquette A; Nicodeme E; Santiago B; Santos L; Smith KJ; Thorpe JH; Thripp G; Trottet L; Walker AL; Ward SA; Wang Y; Wilson S; Pearce AC; Hovnanian A
    J Invest Dermatol; 2021 Sep; 141(9):2272-2279. PubMed ID: 33744298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
    Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
    J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
    Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
    Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
    Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
    J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two siblings affected by Netherton/Comèl syndrome. Diagnostic pathology and description of a new SPINK5 variant.
    Schepis C; Siragusa M; Centofanti A; Vinci M; Calì F
    Dermatol Online J; 2019 Jul; 25(7):. PubMed ID: 31450277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity.
    Descargues P; Deraison C; Bonnart C; Kreft M; Kishibe M; Ishida-Yamamoto A; Elias P; Barrandon Y; Zambruno G; Sonnenberg A; Hovnanian A
    Nat Genet; 2005 Jan; 37(1):56-65. PubMed ID: 15619623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
    Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
    J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiling system for skin kallikrein proteolysis applied in gene-deficient mouse models.
    Horn M; Zbodakova O; Kasparek P; Srp J; Haneckova R; Hradilek M; Mares M; Sedlacek R
    Biol Chem; 2018 Sep; 399(9):1085-1089. PubMed ID: 29885275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.